A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy
Clinical trial NCT04044222 · UNKNOWN
Trial details
- NCT number
- NCT04044222
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-21
- Primary completion
- 2023-07-30
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.